Legal Representation
Attorney
Stacy L. Wu
USPTO Deadlines
Next Deadline
1450 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20240102)
Due Date
January 02, 2030
Grace Period Ends
July 02, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
37 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 20, 2025 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Oct 16, 2025 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
| Oct 16, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Oct 16, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Oct 16, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Oct 16, 2025 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Oct 16, 2025 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Apr 23, 2024 | FINV | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Apr 4, 2024 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Apr 4, 2024 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Apr 2, 2024 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Jan 2, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Jan 2, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Oct 17, 2023 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Oct 17, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Oct 17, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 27, 2023 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Sep 27, 2023 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Sep 27, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Sep 13, 2023 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Sep 13, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 13, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 13, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Sep 7, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Sep 7, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Sep 7, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Sep 7, 2023 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Sep 7, 2023 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Jul 10, 2023 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Jun 15, 2023 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Jun 15, 2023 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| May 7, 2023 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| May 6, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 5, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 4, 2022 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Sep 30, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 29, 2022 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of diabetic macular edema; pharmaceutical preparations for the treatment of angioedema; pharmaceutical preparations for the treatment of hereditary angioedema; pharmaceutical preparations for the treatment of diseases and disorders mediated by the contact activation system; pharmaceutical preparations for the treatment of plasma kallikrein or factor XIIa mediated diseases or disorders
Class 010
Medical and surgical instruments and apparatus for use in the treatment of ophthalmic diseases and disorders, diabetic macular edema, angioedema, hereditary angioedema, diseases and disorders mediated by the contact activation system, and plasma kallikrein or factor XIIa mediated diseases or disorders; drug delivery devices for use in the treatment of ophthalmic diseases and disorders, diabetic macular edema, angioedema, hereditary angioedema, diseases and disorders mediated by the contact activation system, and plasma kallikrein or factor XIIa mediated diseases or disorders
Class 042
Drug discovery services relating to ophthalmic diseases and disorders; drug discovery services relating to diabetic macular edema; drug discovery services relating to angioedema; drug discovery services relating to hereditary angioedema; drug discovery services relating to diseases and disorders mediated by the contact activation system; drug discovery services relating to plasma kallikrein or factor XIIa mediated diseases or disorders
Class 044
Medical and healthcare services relating to ophthalmic diseases and disorders; medical and health care services relating to diabetic macular edema; medical and healthcare services relating to angioedema; medical and healthcare services relating to hereditary angioedema; medical and healthcare services relating to diseases and disorders mediated by the contact activation system; medical and healthcare services relating to plasma kallikrein or factor XIIa mediated diseases or disorders
Additional Information
Design Mark
The mark consists of a stylized letter K with the bottom diagonal leg of the letter K annexed at a right angle with another leg of the same length extending up and out towards the right and a small circle positioned to the right center of the letter K.
Classification
International Classes
005
010
042
044